Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study

References

• Chen XL, Zheng LY, Zhang H, et al. Disease burden and quality of life in patients with psoriasis: an internet-based questionnaire survey. Chin J Dermatol. 2019;52(11):791–795 doi:10.35541/cjd.20190247.
   Google Scholar
• Zhang XJ, Wang G, Zhang FR, Zhang XB, Li B. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023;56(7):573–625 doi:10.35541/cjd.20220839.
   Google Scholar
• Yang Z, Yao X, Wang M, Li H, Li R. Updates in psoriasis diagnosis and treatment status in China: results from the National Psoriasis Center Registry. Chin Med J. 2023;136(23):2874–2876 doi:10.1097/CM9.0000000000002563.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Bao CD, Chen YH, Gu JR, Gao MQ, Huang F. Expert position paper on tuberculosis prevention and management in tumor necrosis factor antagonist application. Chin J Rheumatol. 2013;17(8):508–512.
   Google Scholar
• Wang GQ, Wang FS, Zhuang H, Li TS, Zheng SJ. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019). J Clin Hepatol. 2019;35(12):2648–2669.
   Google Scholar
• Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166–174.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2). Lancet. 2008;371(9625):1675–1684. doi:10.1016/S0140-6736(08)60726-6
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 1). Lancet. 2008;371(9625):1665–1674. doi:10.1016/S0140-6736(08)60725-4
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerback C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi:10.1016/S0140-6736(21)00184-7
   PubMed Web of Science ®Google Scholar
• Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (>/= 6 to <12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–672. doi:10.1111/bjd.19018
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603. doi:10.1016/j.jaad.2015.07.002
   PubMed Web of Science ®Google Scholar
• Tang H, Jin X, Li Y, et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet. 2014;46(1):45–50. doi:10.1038/ng.2827
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet. 2009;41(2):205–210. doi:10.1038/ng.310
   PubMed Web of Science ®Google Scholar
• Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168(3):609–616. doi:10.1111/bjd.12045
   PubMed Web of Science ®Google Scholar
• Cho SI, Kang S, Kim YE, Lee JY, Jo SJ. Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea. J Am Acad Dermatol. 2020;82(5):1243–1245. doi:10.1016/j.jaad.2019.12.033
   PubMed Web of Science ®Google Scholar
• Siegel SAR, Winthrop KL, Ehst BD, Ortega Loayza A. Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C. Br J Dermatol. 2019;180(5):1232–1233. doi:10.1111/bjd.17444
   PubMed Web of Science ®Google Scholar
• Liu S, He Z, Wu W, Jin H, Cui Y. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection. Clin Rheumatol. 2023;42(9):2369–2376. doi:10.1007/s10067-023-06630-8
   PubMed Web of Science ®Google Scholar
• Wu JF, Wu TC, Chen CH, et al. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology. 2010;138(1):165–72 e1–3. doi:10.1053/j.gastro.2009.09.018
   Web of Science ®Google Scholar
• Narinyan W, Poladian N, Orujyan D, Gargaloyan A, Venketaraman V. Immunologic role of innate lymphoid cells against mycobacterial tuberculosis infection. Biomedicines. 2022;10(11):2828. doi:10.3390/biomedicines10112828
   PubMed Web of Science ®Google Scholar
• Tsuda K, Yamanaka K, Kondo M, et al. Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. PLoS One. 2012;7(12):e51819. doi:10.1371/journal.pone.0051819
   PubMed Web of Science ®Google Scholar
• Porzsolt F, Eisemann M, Habs M, Wyer P. Form follows function: pragmatic controlled trials (PCTs) have to answer different questions and require different designs than randomized controlled trials (RCTs). Z Gesundh Wiss. 2013;21(3):307–313. doi:10.1007/s10389-012-0544-5
   PubMedGoogle Scholar
• Wang G, Zhang XJ, Chen AJ, Gao XH, Gu H. Guidelines for the treatment of psoriasis with biologic agents in China (2021). Chin J Dermatol. 2021;54(12):1033–1047.
   Google Scholar
• Haas MK, Belknap RW. Diagnostic tests for latent tuberculosis infection. Clin Chest Med. 2019;40(4):829–837. doi:10.1016/j.ccm.2019.07.007
   PubMed Web of Science ®Google Scholar
• Gong W, Wu X. Differential diagnosis of latent tuberculosis infection and active tuberculosis: a key to a successful tuberculosis control strategy. Front Microbiol. 2021;12:745592. doi:10.3389/fmicb.2021.745592
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200.
   PubMedGoogle Scholar
• Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of D. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483. doi:10.1111/jdv.15340
   PubMed Web of Science ®Google Scholar
• Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201–222. doi:10.1111/1346-8138.15196
   PubMed Web of Science ®Google Scholar
• Alpalhao M, Duarte J, Diogo R, et al. Lower limbs are the most difficult-to-treat body region of patients with psoriasis: pooled analysis of CLEAR and CLARITY studies of secukinumab versus ustekinumab by body region. BioDrugs. 2022;36(6):781–789. doi:10.1007/s40259-022-00558-2
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854. doi:10.1111/bjd.12214
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Pavia G, Valenti M, et al. Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study. Dermatol Ther. 2022;12(5):1263–1270. doi:10.1007/s13555-022-00726-w
   Web of Science ®Google Scholar
• Mastorino L, Dapavo P, Trunfio M, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in Northern Italy. Acta Derm Venereol. 2022;102:adv00821. doi:10.2340/actadv.v102.1982
   PubMed Web of Science ®Google Scholar
• Torres T, Chiricozzi A, Puig L, et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol. 2024;25(2):333–342. doi:10.1007/s40257-024-00845-4
   PubMed Web of Science ®Google Scholar
• Ibba L, Gargiulo L, Vignoli CA, et al. Safety of anti-IL-23 drugs in patients with moderate- to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study. J Dermatol Treat. 2023;34(1):2241585. doi:10.1080/09546634.2023.2241585
   PubMed Web of Science ®Google Scholar